PatentsRegulationCOVID-19: How to Implement the Ex Officio License – Elisabeth Berthet ⋅ Matthieu Dhenne ⋅ Lionel Vial
Current research for COVID-19 treatments is based on known pharmaceutical active ingredients covered by industrial property titles (patents or supplementary protection certificates). These titles confer to their owner an exclusive right of exploitation on the claimed substances. Consequently, the manufacture by third parties of anti-COVID-19 medicinal products which composition would include protected molecules will require […]